title: Selection of an M184V mutation in the cerebrospinal fluid of a treatment-naive HIV-infected individual starting darunavir-based therapy.
abstract: Here, we describe a newly diagnosed HIV-1-infected patient, in whom shortly after the initiation of a darunavir-based regimen, the HIV-1 virus exclusively mutated in the cerebrospinal fluid (CSF), leading to an increase in CSF HIV-1 RNA load and neurological complaints.
authors: Department of Medical Microbiology, Section Experimental Virology, Center for Infection and Immunity Amsterdam, Amsterdam, The Netherlands.
authors: Marion
authors: M
authors: Cornelissen
authors: Nicole K T
authors: NK
authors: Back
authors: David M
authors: DM
authors: Burger
authors: Petra
authors: P
authors: Blom
authors: Peter
authors: P
authors: Portegies
authors: Jan M
authors: JM
authors: Prins
authors: Marc
authors: M
authors: van der Valk
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000069454:Darunavir; D024882:Drug Resistance, Viral / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000145:classification / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D010802:Phylogeny; D012367:RNA, Viral / Q000134:cerebrospinal fluid*; D013449:Sulfonamides / Q000627:therapeutic use*; D019562:Viral Load; D054302:pol Gene Products, Human Immunodeficiency Virus / Q000235:genetics*
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral; D013449:Sulfonamides; D054302:pol Gene Products, Human Immunodeficiency Virus; D000069454:Darunavir